Obesity – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Description
Obesity Market Outlook
Thelansis’s “Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
9Obesity Overview
Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of multiple comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance—calories consumed exceeding calories expended—being the central driver.
Diagnosis is typically based on body mass index (BMI ≥30 kg/m²), though additional measures such as waist circumference and body composition provide better insight into cardiometabolic risk. Beyond physical health, obesity is also associated with reduced quality of life, psychological distress, and social stigma.
The disease is increasingly recognized as a biologically regulated, chronic condition, requiring long-term management. Treatment approaches are multifaceted and include:
Lifestyle modification and nutritional counseling
Physical activity and behavioral therapy
Pharmacotherapy
Bariatric surgery in severe cases
Recent therapeutic advancements—particularly GLP-1 and dual incretin-based therapies—have significantly improved clinical outcomes, enabling sustained weight loss and transforming the treatment paradigm. Despite these advances, obesity remains a major global public health challenge, requiring scalable prevention strategies and personalized long-term care models.
Key Highlights
The diagnosed obesity population in Germany is projected to grow significantly, increasing from 7.2 million in 2025 to 14.2 million by 2035, reflecting a high growth trajectory (7% CAGR).
Obesity represents a high-prevalence, high-burden disease, with substantial long-term healthcare costs driven by associated comorbidities.
Despite large patient numbers, treatment penetration remains low, with many patients managed primarily through lifestyle interventions.
Market Overview
The obesity market is undergoing rapid expansion, driven by high-efficacy therapies and increasing treatment uptake.
The obesity market in France is projected to grow from $410M in 2025 to $1.57Bn by 2035, reflecting a strong CAGR of 14–15%.
The diagnosed population in Germany is expected to grow at ~7% CAGR, significantly expanding the addressable market.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Thelansis’s “Obesity Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Obesity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
9Obesity Overview
Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of multiple comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance—calories consumed exceeding calories expended—being the central driver.
Diagnosis is typically based on body mass index (BMI ≥30 kg/m²), though additional measures such as waist circumference and body composition provide better insight into cardiometabolic risk. Beyond physical health, obesity is also associated with reduced quality of life, psychological distress, and social stigma.
The disease is increasingly recognized as a biologically regulated, chronic condition, requiring long-term management. Treatment approaches are multifaceted and include:
Lifestyle modification and nutritional counseling
Physical activity and behavioral therapy
Pharmacotherapy
Bariatric surgery in severe cases
Recent therapeutic advancements—particularly GLP-1 and dual incretin-based therapies—have significantly improved clinical outcomes, enabling sustained weight loss and transforming the treatment paradigm. Despite these advances, obesity remains a major global public health challenge, requiring scalable prevention strategies and personalized long-term care models.
Key Highlights
The diagnosed obesity population in Germany is projected to grow significantly, increasing from 7.2 million in 2025 to 14.2 million by 2035, reflecting a high growth trajectory (7% CAGR).
Obesity represents a high-prevalence, high-burden disease, with substantial long-term healthcare costs driven by associated comorbidities.
Despite large patient numbers, treatment penetration remains low, with many patients managed primarily through lifestyle interventions.
Market Overview
The obesity market is undergoing rapid expansion, driven by high-efficacy therapies and increasing treatment uptake.
The obesity market in France is projected to grow from $410M in 2025 to $1.57Bn by 2035, reflecting a strong CAGR of 14–15%.
The diagnosed population in Germany is expected to grow at ~7% CAGR, significantly expanding the addressable market.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Table of Contents
158 Pages
- 1. Key Findings and Analyst Commentary
- 1.1 Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.
- 2. Disease Context
- 2.1 Disease definition, classification, etiology and pathophysiology, drug targets, etc.
- 3. Epidemiology
- 3.1 Key takeaways
- 3.2 Incidence / Prevalence
- 3.3 Diagnosed and Drug-Treated populations
- 3.4 Comorbidities
- 3.5 Other relevant patient segments
- 4. Market Size and Forecast
- 4.5 Key takeaways
- 4.6 Market drivers and constraints
- 4.7 Drug-class specific trends
- 4.8 Country-specific trends
- 5. Competitive Landscape
- 5.1 Current therapies
- 5.1.1 Key takeaways
- 5.1.2 Dx and Tx journey/algorithm
- 5.1.3 Key current therapies – profiles and KOL insights
- 5.2 Emerging therapies
- 5.2.1 Key takeaways
- 5.2.2 Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- 5.2.3 Notable early-phase pipeline
- 6. Unmet Need and TPP Analysis
- 6.1 Top unmet needs and future attainment by emerging therapies
- 6.2 TPP analysis and KOL expectations
- 7. Regulatory and Reimbursement Environments (by country and payer insights)
- 8. Appendix (e.g., bibliography, methodology)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
